David Jinich, MD
Cardiovascular Disease · Christiansburg, VANPI 1861447500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,000 of the $38,658 with a category attached, or 77.6%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 78.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $15,256 and has fallen 96.2% since, to $584 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $146.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30K
- Abbott$3K
- Penumbra, Inc.$2K
- Medtronic$2K
- E.r. Squibb & Sons, L.L.C.$468
- Boston Scientific$213
- plus $921 from 17 others
What the payments were for
- Speaking & faculty fees$30,00078%
- Travel & lodging$3,5139%
- Food & beverage$5,14513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 60 | $30,308 |
| Abbott | 100 | $3,404 |
| Penumbra, Inc. | 10 | $1,831 |
| Medtronic(2 entities) | 29 | $1,513 |
| E.r. Squibb & Sons, L.L.C. | 21 | $468 |
| Boston Scientific | 9 | $213 |
| Shockwave Medical, Inc | 5 | $130 |
| Terumo Medical Corporation | 6 | $128 |
| Cardiovascular Systems Inc. | 1 | $110 |
| Novartis | 4 | $93 |
| Pfizer | 4 | $89 |
| ZOLL Respicardia, Inc. | 1 | $66 |
| Philips North America LLC | 1 | $61 |
| Johnson & Johnson | 3 | $46 |
| Bridgebio Pharma, Inc. | 1 | $41 |
| Merck | 1 | $33 |
| Amgen | 1 | $26 |
| Inari Medical, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Anumana, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$30,000
- Indigo$2,280
- Xience V coronary stent system$1,463
- Micra$470
- CAMZYOS$125
- JOT DX$111
- Diamondback Peripheral$110
- ENSITE$109
How this compares
$38,658 in reported general payments places this provider in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $134,432 |
| EntrestoSacubitril/Valsartan | 45 | $55,398 |
| Repatha SureclickEvolocumab | 29 | $40,225 |
| XareltoRivaroxaban | 28 | $36,390 |
| Metoprolol Succinate | 150 | $2,249 |
| Atorvastatin Calcium | 135 | $1,758 |
| Rosuvastatin Calcium | 70 | $1,626 |
| Ezetimibe | 27 | $790 |
| Losartan Potassium | 68 | $781 |
| Amiodarone Hcl | 32 | $734 |
| Carvedilol | 74 | $686 |
| Flecainide Acetate | 11 | $675 |
| Potassium Chloride | 31 | $642 |
| ClopidogrelClopidogrel Bisulfate | 34 | $564 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $134,432105 claims |
| NovartisEntresto | $93 | $55,39845 claims |
| Johnson & JohnsonXarelto | $46 | $36,39028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Christiansburg
- Thomas VacekChristiansburg$22K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.